SCHEDULE: Vanguard Discloses 5.27% Stake in Ocugen Inc

The Vanguard Group reported a 5.27% beneficial ownership stake in Ocugen Inc's common stock as of December 31, 2025, in a Schedule 13G filing.

Summary

• The Vanguard Group reported beneficial ownership of 16,475,562 shares of Ocugen Inc common stock.
• This represents 5.27% of Ocugen Inc's outstanding common stock.
• The filing indicates shared voting power over 1,981,345 shares and shared dispositive power over all 16,475,562 shares.
• The filing date is January 30, 2026, with the event date being December 31, 2025.
• The Vanguard Group, Inc. underwent an internal realignment on January 12, 2026, affecting its portfolio management and proxy voting services.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it confirms significant institutional ownership by a reputable firm like Vanguard, which can be a sign of stability and liquidity for Ocugen Inc's stock.

Positives

• Significant institutional ownership by The Vanguard Group, a major investment firm, which can signal confidence in Ocugen Inc.
• The acquisition of shares was in the ordinary course of business, not for control purposes, indicating a passive investment strategy.

Future Outlook

The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. following an internal realignment effective January 12, 2026.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes by major investment firms. The Vanguard Group's 5.27% stake in Ocugen Inc indicates a notable passive investment, aligning with typical index fund or broad market ETF strategies that often result in such disclosures for publicly traded companies.

Stakeholder Impact

• Shareholders: Increased institutional ownership may enhance liquidity and provide a level of confidence.
• The Vanguard Group's Clients: Their investments in Ocugen Inc are managed under a new internal structure post-realignment.

Next Steps

• The Vanguard Group's subsidiaries or business divisions are expected to report beneficial ownership separately in future filings.

Key Dates

Keywords

Ocugen Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, Ocular Therapeutics